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Abstract
Background: It has been shown that approximately half of survivors of childhood acute lymphoblastic leukemia
(ALL) have symptomatic late effects (LE) that may be severe or life-threatening. The aim of our study was to assess
the health status of childhood ALL survivors after over 10 years of follow-up and to assess its relationships with gene
polymorphisms, numbers and types of LEs, as well as with intensity of chemotherapy and cranial radiotherapy (CRT).
Methods: We conducted a telephone survey in 125 ALL survivors (median time from completion of treatment was
12 years) and compared the results with those obtained in our previous study. Most of the patients were followed-up
by local providers.
Results: The prevalence of LEs of approximately 50% was similar in both study groups. More than one LE was found in
almost 25% of patients. Endocrine LEs were less frequent than in our previous study (44% vs 22%), probably due to
underdiagnosis. The prevalence of hepatitis B/C decreased from 30%/50 to 18% (counted together), and
prevalence of neurologic LEs decreased from 18 to 6%. The increase in the rate of second malignancies was
not significant (2% vs. 3%). Sixty four percent of patients continued their education at the time of the study.
Approximately 51% of ALL survivors who have completed their education by the time of the study had no
permanent employment, including 4 mothers of infants and 3 persons qualified for a disability living
allowance. These employment problems may have been due to cognitive impairment. The offspring of the
ALL survivors included 11 children, all of them healthy. Further analysis showed higher prevalence of hepatitis
in patients treated with CRT (p = 0.0001). Genetic studies revealed higher prevalence of hepatitis in patients
homozygous for the rs9939609A variant of the FTO gene compared with other patients (p = 0.03). Moreover,
wild-type rs1137101 polymorphism (Q223R) of the and leptin receptor gene was more frequent in patients
with psychological LEs (p = 0.03).
Conclusions: The prevalence of LEs in ALL survivors is of key importance. The transition of childhood ALL
survivors from pediatric to adult care should be urgently improved to maintain continued follow-up provide
high-quality care.
Trial registration: Bioethics Committee of the Jagiellonian University approved the study protocol.
Registration number: KBET/113/B/2006.
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Background
In our previous study [1], conducted from 1994 to 2000
in the Late Effects Outpatient Clinic of the Department
of Oncology and Hematology, Institute of Pediatrics,
Jagiellonian University, Krakow, Poland, we studied 255
patients, aged 4 to 28 years (median 12 years), who have
completed acute lymphoblastic leukemia (ALL)
treatment. The median time from completion of the
treatment to enrollment in the study was 3 years. More
than 50% of ALL survivors had late effects (LE) of treat-
ment. The most frequent LEs were cognitive impairment
and abnormalities of growth and body weight. Second
neoplasms were diagnosed in 2% of patients. Endocrine
LEs of any type were observed in 40% of ALL survivors.
Other LEs were thyroid disorders, hypogonadism,
premature puberty, seen in 11, 3 and 1% of patients,
respectively. Menstruation disturbances were observed
in 2% of female patients. Results of psychological tests of
the ALL survivors were below the level of their healthy
peers, mainly in mathematical skills, and the rate of test
processing was slower. Girls had worse results than
boys, and cranial radiotherapy (CRT) was implicated as
the main cause of the impairments. Neurological LEs
were seen in 18% of patients, and behavioral problems
in 20% of patients. Serological markers of hepatitis B
virus infection were positive in more than 30% of patients,
and markers of hepatitis C virus infection in almost 50%
of patients. Patients were followed-up in the clinics of the
Institute of Pediatrics until they were 18 years old, and
then they were referred to an adult outpatient center at
the University Hospital in Krakow. The aim of our study
was to assess the health status of childhood ALL survivors
after more than 10 years of follow-up.
Polymorphisms of the genes responsible for regulation
of metabolism can be associated with various LEs [2–4].
As the regulation of the insulin pathway is responsible
for proliferation of cell lineages [5, 6], the role of poly-
morphisms of the genes involved in this pathway in the
emergence of LEs of ALL treatment is interesting. In
vitro, recombinant FTO takes part in catalyzing demeth-
ylation of certain methyl nucleotides in single-stranded
DNA and RNA, which suggests a potential role of FTO
in nucleic acid repair or modification. The FTO gene
polymorphism is associated with an increase in the risk
of obesity, as well as type 2 diabetes, heart failure, coron-
ary heart disease, lifetime all-cause and ischemic stroke,
hypertension, dyslipidemia, metabolic syndrome, and
mortality. Moreover, it is also associated with increased
fasting glucose and insulin levels, 2-h OGTT test results,
HbA1c, blood pressure, lipid levels, liver function tests,
and inflammatory markers, which are potential risk fac-
tors of the disorders mentioned above [7]. Obesity is also
considered a risk factor for certain cancers [8]. Leptin
receptor gene (LEPR) encodes the leptin receptor that is
activated by leptin and has effects on food intake in
humans. Mutations of the leptin gene and leptin receptor
gene in obese patients suggest that leptin takes part in
regulation of energy balance [9]. LEPR gene polymor-
phisms, K109R and Q223R, located in exons 4 and 6, are
implicated in the regulation of lipid metabolism and insu-
lin resistance [10]. Genetic associations between these two
polymorphisms and obesity parameters, including insulin
resistance, glucose levels and serum lipid profile, have been
reported [11, 12]. Moreover, Q223R polymorphism of the
LEPR gene is associated with metabolic syndrome [13].
Based on this theoretical background we investigated
associations between the selected gene polymorphisms
and prevalence of LEs in pediatric ALL survivors.
Methods
The study cohort included 125 patients who have previ-
ously completed ALL treatment and were available for a
telephone survey conducted by a physician working at the
Outpatient Clinic of the Department of Oncology and
Hematology, Institute of Pediatrics, Jagiellonian University.
Majority of them (65 out of 125) were included in our pre-
vious study. ALL therapy was conducted from 16/01/1984
to 8/11/2004 according to a modified BFM regimen with
subsequent revisions (100 patients) or a New York regimen
(25 patients). Details concerning treatment regimens were
published elsewhere [14–16]. Age at ALL diagnosis was
1–18.5 years (median 4.4, mean 4.2 years.) Details of the
patients are provided in Table 1.
All patients included in the survey were interviewed
by the same physician and the questions concerned:
education/employment, health problems, established
diagnoses, recent outpatient visits or hospital admis-
sions, medications in use, marital status and offspring.
Data regarding the polymorphisms studied in the
patients were previously published elsewhere [17, 18].
Correlations between gene polymorphisms and the
numbers and types of LEs were analyzed with respect to
the intensity of chemotherapy (less intensive BFM regi-
mens for standard/ intermediate-risk patients vs. more
intensive New York regimens for high-risk patients, and
BFM regimen for relapsed ALL) and to CRT. Descriptive
statistics, odds ratios (OR) with 95% confidence interval,
and Fisher’s exact test were used.
Local bioethics committee approved the study protocol.
All parents and adolescent patients signed an informed
consent before blood sample collection.
Results
The study cohort included 125 survivors of childhood ALL
aged from 10.6 to 33 years (median 20.3 years); 58 patients
(46%) were male and 67 patients (54%) were female. In 61
patients CRT was administered (doses: 14 to 24 Gy;
median 18.2 Gy) according to the treatment regimens. A
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second CRT was performed in 3 patients (15 Gy, 18 Gy
and 18.2 Gy), and spinal radiotherapy in one patient.
Testicular radiotherapy was used in 2 patients (18 Gy and
21 Gy). In 95 (76%) patients less intensive ALL treatment
regimens were used, and 30 (24%) patients were treated ac-
cording to the more intensive regimens. Two patients com-
pleted a second course of treatment for relapsed ALL. One
of them was treated with hematopoietic cell transplantation
from a matched sibling donor. The duration of ALL treat-
ment was from 1.7 to 4.2 years (median 3.2 years).
LEs were seen in 65 patients (52%), including one
LE in 35 patients (28%), and > 1 LE in 30 patients
(24%). Two LEs were seen in 20 patients (16%), 3 LEs
in 8 patients (6%), and 5 and 7 LEs in 1 patient each
(about 1%).
The most frequent LEs (Table 2) were endocrine dis-
turbances, hepatitis, psychological and neurological ab-
normalities, which were seen in 22, 18, 10 and 6%
patients, respectively. Further analysis revealed increase
in the prevalence of hepatitis in patients treated with
CRT (p = 0.0001).
Sixty four percent of the patients continued their educa-
tion. About 51% of the patients who have completed their
education had no permanent employment, including 4
mothers of children below 1 year of age and 3 persons who
have qualified for a disability living allowance (Table 3).
The offspring of ALL survivors included 11 children
(age from 0.3 years to 6 years; 7 girls and 4 boys). All of
them were healthy.
Genetic studies revealed higher prevalence of hepatitis
in individuals homozygous for the rs9939609A variant of
the FTO gene compared with other patients (p = 0.03).
Moreover, psychosocial complications were seen more
frequently in patients with wild-type rs1137101
Table 1 Characteristics of the study group
Parameter All patients Cranial
radiotherapy
No cranial
radiotherapy
Total (n) 125 61 64
Female 67 33 34
Male 58 28 30
Treatment regimen (n)
BFM 100 37 63
New York 25 24 1
Relapses 5 4 1
CNS 3 2 1
Testes 2 2 0
Intensity of treatment
regimen (n)
High intensity 30 30 0
Low intensity 95 28 67
Age at ALL diagnosis
(years)
1–18.5
(median 4.4)
1.9–18.5
(median 4)
1–10.3
(median 4.8)
Age at enrollment (years) 10.6–33
(median 20.3)
12.2–33
(median 24.7)
10.6–25.6
(median 17.7)
Time from completion
of ALL treatment (years)
4.3–25.7
(median 11.7)
4.3–25.7
(median 15)
5.1–21
(median 10.3)
Table 2 Late effects of ALL treatment
Late effect n %
Endocrine – hyperthyroidism, hypothyroidism,
hyperprolactinemia, testosterone deficiency,
growth hormone deficiency, obesity, infertility
27 22
Hepatitis B or C 23 18
Psychological – dyslexia, impairment of cognitive
function and memory
12 10
Neurological – recurrent headache, epilepsy 7 6
Gynecological – menstruation disorders 6 5
Psychiatric - depression, phobia, anorexia 4 3
Second neoplasm – meningioma (2 cases), cervical
cancer, haeeamangioma of the liver
4 3
Musculoskeletal – bone and muscle pain, vertebral
column pain, scoliosis, osteoporosis
9 7
Allergy 3 2
Dermatological – psoriasis, eczema 3 2
Nephrological – nephrolithiasis, nephropathy 3 2
Gastrointestinallogical – cholelithiasis, gastritis 3 2
Pulmonary – asthma, recurrent pneumonia 2 1.6
Ocular – diplopia 1 0.8
Cardiovascular – hypertension, hypotension 2 1,6
Ear, nose throat – hearing impairment 1 0.8
Immunological - immunodeficiency 1 0.8
Table 3 Employment/education status in ALL survivors
Status n Additional information
Disability pension 3
Unemployment 20 Education level:
Primary school – 11
Trained to profession
after primary school – 3
Technical primary school – 3
Technical high school – 1
High school – 1
University – 1
Physical labor 2 Primary school
Employment after completing
education
4 Technical primary school
8 High school/Technical high
school
8 University
Primary school 12 Education in progress
Primary technical school 3
Secondary school 23
High school/Technical high school 22
University 20
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polymorphism (Q223R) of LEPR gene (p = 0.03). Numbers
of patients in whom the studied polymorphisms were
found are presented in Tables 4 and 5.
In the analysis of the entire study cohort, no statisti-
cally significant differences in the studied gene variants
and ALL treatment intensity were found.
Discussion
Currently, a combined multimodal therapy (multi-agent
intensive chemotherapy, radiotherapy and stem cell
transplantation) allows for achieving a complete cure in
approximately 90% of children with ALL [19]. Growing
numbers of young and middle-aged (15–45 years)
childhood cancer survivors require skilled professionals
to take care of this category of patients. In 1990, one in
1000 young adults was a survivor of childhood cancer,
whereas in 2010 the rate was one in 250 [20]. In 1994
Childhood Cancer Survivor Study (CCSS) was started in
the USA. It is still ongoing and it currently includes
follow-up data of more than 20,000 childhood cancer
survivors who have completed therapy more than 5 years
ago [21]. It was shown that approximately half of the
survivors have symptomatic LEs, including severe and
life threatening LEs in 21 and 14% of them, respectively
[22]. The LEs include: premature mortality, a second malig-
nant neoplasm, organ dysfunction (e.g. heart, lung, gonads),
growth impairment, delayed puberty, infertility, impairment
of cognitive function. These may cause employment and in-
surance problems and impaired quality of life [20, 22–46].
Use of radiotherapy and the type of cancer are the key
risk factors for LE development [20, 22, 23]. Prevalence
of LEs was higher in patients treated for solid tumors
compared with those treated for leukemia or lymphoma
[20, 22].
It is estimated that 1 in 715 young adults in the UK are
survivors of childhood cancer and ALL was the diagnosis
in 15% of the survivors aged from 20 to 39 years [47].
About 28% of ALL survivors have psychological sequelae
[48]. Chronic conditions are found in 66 to 88% of child-
hood cancer survivors, and their prevalence increases with
age [43]. The prevalence of LEs in our cohort was within
the ranges reported in the literature. However, given the
methodology of our study, we may have underestimated
the prevalence of LEs in our study population.
In the present study we assessed the prevalence of LEs
using a telephone survey conducted in patients who
have previously been treated at our center. This is an
important limitation of the study. However, the calls
were performed by the same physician who has previ-
ously taken care of the patients at the Late Effects Out-
patient Clinic, which in turn improves the quality of the
study. We were able to reach approximately 50% of the
patients included in our previous study in the late 1990s.
The difference in a median follow-up between both
studies was approximately 9 years (3 vs 12 years). Only a
few patients remained in a continued care of an
outpatient clinic for adult survivors of childhood cancer.
Almost all other patients were in a care of local health-
care providers. Prevalence of LEs in both studies was the
same (50%). More than one LE was found in almost 25%
of the patients. Endocrine LEs were less frequently seen
in our present study (44% vs 22%). This was probably
due to underdiagnosis. The prevalence of hepatitis B/
hepatitis C decreased from 30%/50 to 18% (counted
together), and prevalence of neurological LEs decreased
from 18 to 6%. The increase in the rates of second ma-
lignant neoplasms was not significant (2% vs. 3%). The
study revealed higher prevalence of hepatitis in patients
treated with CRT (p = 0.0001) and in patients homozy-
gous for the rs9939609A variant of the FTO gene (which
in our previous study was associated with higher BMI)
compared with other patients. This may be explained by
the use of CRT in the more intensive treatment regi-
mens, which increased the risk of infection, whereas
obesity, which was more prevalent in patients homozy-
gous for rs9939609A variant of the FTO gene, causes
impaired liver function due to activation of the insulin
pathway and may be associated with higher susceptibility
to infections. However, we are unable to explain why
wild-type Q223R polymorphism of LEPR gene was more
frequently found in patients with psychological LEs
(p = 0.03). Interestingly, as in our previous study, we
were unable to establish correlations between the tested
Table 4 Rates of the studied polymorphisms
Genotype
FTO gene polymorphism rs9939609 (c.28-23,525 T > A) TT TA AA
Total (n) 58 36 31
CRT+ 25 17 17
CRT- 33 19 14
Leptin receptor gene (LEPR) polymorphism rs1137100
(K109R; c.326A > G)
AA AG GG
Total (n) 58 59 8
CRT+ 30 27 4
CRT- 28 32 4
Leptin receptor gene (LEPR) polymorphism rs1137101
(Q223R; c.668A > G)
AA AG GG
Total (n) 69 28 28
CRT+ 30 16 15
CRT- 39 12 13
Leptin receptor gene (LEPR) polymorphism rs1805094
(K656 N; c.1968G > C)
GG GC CC
Total (n) 25 99 1
CRT+ 10 50 1
CRT- 15 49 0
CRT cranial radiotherapy
Kwiecinska et al. Italian Journal of Pediatrics  (2018) 44:92 Page 4 of 8
polymorphisms and the development of LEs in the
context of intensity of chemotherapy. It was probably
due to a limited number of patients included in the
study. In the future, genetic studies (assessment of gene
expression profile, GWAS) might be useful in stratifica-
tion of patients, personalization of therapy, outcome
prediction and estimation of the risk of LEs, as well as in
identification of new therapeutic targets.
In our previous study, quality of life was assessed using
a score (1–5) defined by Skoczen [1]. The average score
was 4.4 points. Unfortunately, the score was not
included in the current telephone survey questionnaire.
Sixty four percent of childhood ALL survivors contin-
ued their education. Approximately 51% of patients who
completed the education had no permanent employ-
ment, including 4 mothers of children below 1 year of
age and 3 persons who have qualified for a disability
living allowance. The offspring of the ALL survivors
included 11 children (age from 0.3 years to 6 years; 7
girls and 4 boys). All of them were healthy.
As it was shown in other studies, cognitive impairment
may be the reason for employment problems [23, 30,
35]. The unemployment rate in the study cohort was
significantly higher than in age-matched general popula-
tion in Poland (11% unemployed, 15% temporarily
unemployed) [49]. The levels of education of survivors
of childhood malignancies are generally lower than in
the healthy population of the same age. In our study, a
university degree was achieved by 20% of patients who
completed their education, compared with 31% in the
age-matched Polish population [50]. One of the most
important issues in many pediatric oncology centers is
the transition of patients > 18 years of age to adult
oncology centers [51, 52]. Our procedure is to refer the
survivors to the University Outpatient Clinic. Unfortu-
nately, most of our patients are not satisfied with the
care offered by the adult clinic. Therefore, they are most
frequently followed-up by local healthcare providers,
who have no skills necessary for comprehensive care of
childhood cancer survivors. This may cause frequent
Table 5 Genotypes of the FTO and LEPR variants in patients with the most common LEs; statistical analysis using Fisher’s exact test
(NS – not significant)
FTO gene polymorphism rs9939609 (c.28-23,525 T > A)
LEs Genotypes Number of cases with LEs / without LEs Statistical significance (Fisher’s exact test)
TT TA AA
Endocrine disturbances 7/29 11/47 7/24 NS
Hepatitis 9/27 4/54 10/21 p = 0.004 (AA vs. TT); p = 0.03
(AA vs. AT + TT)
Psychological abnormalities 2/34 8/50 1/30 NS
Leptin receptor gene (LEPR) polymorphism rs1137100 (K109R; c.326A > G)
LEs Genotypes Number of cases with LEs / without LEs Statistical significance (Fisher’s exact test)
AA AG GG
Endocrine disturbances 9/49 14/45 2/6 NS
Hepatitis 12/46 9/50 2/6 NS
Psychological abnormalities 8/50 4/55 0/8 NS
Leptin receptor gene (LEPR) polymorphism rs1137101 (Q223R; c.668A > G)
LEs Genotypes Number of cases with LEs / without LEs Statistical significance (Fisher’s exact test)
AA AG GG
Endocrine disturbances 16/53 5/23 4/24 NS
Hepatitis 11/58 6/22 6/22 NS
Psychological abnormalities 11/58 1/27 0/28 p = 0.03 (AA vs. GG)
Leptin receptor gene (LEPR) polymorphism rs1805094 (K656 N; c.1968G > C)
LEs Genotypes Number of cases with LEs / without LEs Statistical significance (Fisher’s exact test)
GG GC CC
Endocrine disturbances 6/19 19/80 0/1 NS
Hepatitis 3/22 19/80 1/0 NS
Psychological abnormalities 2/23 10/89 0/1 NS
Statistically significant differences were found in the prevalence of hepatitis in patients with FTO gene polymorphism rs 9939609 (c.28- 23,525 T>A) – p = 0.004 (AA vs. TT);
p = 0.03 (AA vs. AT + TT) and in the prevalence of psychological abnormalities in patients with LEPR polymorphism rs1137101 (Q223R; c.668A > G) – p = 0.03 (AA vs. GG)
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underdiagnosis of LEs due to the limited awareness. This
is the first study of survivors of childhood ALL that
describes the current situation of this group of patients
in Poland. We found shortages of appropriate medical
care of these patients due to a lack of awareness in
patients, physicians and health care providers. Because
of inefficient organization and limited resources, the
diagnosis and treatment of LEs were delayed.
Well-designed protocols regulating the transition of
patients from pediatric to adult outpatient care are
necessary to improve this situation. Outpatient clinics
should include multidisciplinary care covering most com-
mon LEs. Appropriate communication and data exchange
between pediatric and adult healthcare providers should
be ensured, with joint discussion on specific recommenda-
tions in particular patients, where necessary. It would be
beneficial for the childhood cancer survivors, particularly
those who have completed their therapy long time ago, to
participate in conferences and use internet resources to
provide them with access to comprehensive information
on their health, quality of life, education and employment.
Conclusions
The prevalence of LEs in childhood ALL survivors
remains a crucial issue. Most of the patients are inad-
equately followed-up. The transition of pediatric patients
to adult care should be urgently improved to maintain
long-term follow up and provide high quality of care.
Higher prevalence of hepatitis in individuals homozy-
gous for the rs9939609A variant of the FTO gene might
be associated with prolonged impairment of liver func-
tion thus causing higher susceptibility to infections.
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